PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homologous recombination (HR) repair. However, as HR-deficient tumors represent only a small fraction of endometrial cancers, the therapeutic utility of PARP inhibitors i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, X, Gao, J, Luo, F, Rui, C, Zheng, T, Wang, D, Wang, Y, Roberts, T M, Liu, P, Zhao, J J, Cheng, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799770/
https://www.ncbi.nlm.nih.gov/pubmed/28945226
http://dx.doi.org/10.1038/onc.2017.326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799770/
https://www.ncbi.nlm.nih.gov/pubmed/28945226
http://dx.doi.org/10.1038/onc.2017.326

Ejemplares similares